Generic Name and Formulations:
Progesterone (micronized) 8% (90mg/applicatorful); vaginal gel; contains mineral oil.
Indications for CRINONE:
Progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency.
Supplementation: 1 applicatorful intravaginally once daily. Replacement: 1 applicatorful intravaginally twice daily. If pregnancy occurs, may continue treatment until placental autonomy is achieved (10–12 weeks).
Undiagnosed vaginal bleeding. Breast or genital carcinoma. Liver dysfunction or disease. Missed abortion. Thrombophlebitis or thromboembolic disorders.
Conditions aggravated by fluid retention. Depression. Include Pap smear with pretreatment exam. Discontinue if signs of thrombotic disorders (eg, thrombophlebitis, cerebrovascular disorders, pulmonary embolism, retinal thrombosis) occur. Pregnancy: see literature. Nursing mothers.
Allow at least 6 hours between administration of this and other vaginally-administered products.
Mastodynia, constipation, somnolence, GI upset, headache, abdominal/perineal pain, nervousness, cramps, nocturia, depression, decreased libido, arthralgia, bloating, pain, vaginal candidiasis/discharge, dizziness, dyspareunia, pruritus genital, allergy, fatigue, urinary tract infection, others.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Unintended Pregnancy Common in Women With Epilepsy
- Aggressive Blood Pressure Lowering in Intracerebral Hemorrhage May Be Harmful
- Risk of Opioid-Benzodiazepine Overlap Up for Dual Prescribing
- Minority Residents Experience Burdens Linked to Race/Ethnicity
- Tips Provided for Budgeting in Medical Residency